Skip to main content
SpringerLink
Log in

Diabetes Mellitus and Metabolic Syndrome

  • Chapter
Biomarkers of Cardiometabolic Risk, Inflammation and Disease

  • 878 Accesses

Abstract

Type 2 diabetes mellitus and metabolic syndrome are two highly prevalent clinical entities in our population and threaten to become a true pandemic. While there are still gaps in medical knowledge about the pathophysiological mechanisms leading to the development of both conditions, a significant effort has been made to study them in detail. Inflammation has been recognized as a major player in all this, and the advancement of knowledge in this area has been fruitful. This chapter will address the inflammatory mechanisms underlying these entities, starting with a more mechanistic and molecular perspective and ending in a more clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–28.

    Article  CAS  PubMed  Google Scholar 

  2. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7.

    Article  CAS  PubMed  Google Scholar 

  3. Martín-Cordero L, García JJ, Hinchado MD, Ortega E. The interleukin-6 and noradrenaline mediated inflammation-stress feedback mechanism is dysregulated in metabolic syndrome: effect of exercise. Cardiovasc Diabetol. 2011;10:42.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Pedersen BK. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochem. 2006;42:105–17.

    Article  CAS  PubMed  Google Scholar 

  5. Mathis D, Shoelson S. Immunometabolism; an emerging frontier. Nat Rev Immunol. 2011;11(2):81–93.

    Article  CAS  PubMed  Google Scholar 

  6. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005;46(11):1978–85.

    Article  CAS  PubMed  Google Scholar 

  7. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–50.

    Article  CAS  PubMed  Google Scholar 

  8. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347–55.

    Article  CAS  PubMed  Google Scholar 

  9. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Hoch M, Eberle AN, Peterli R, Peters T, Seboek D, Keller U, et al. LPS induces interleukin-6 and interleukin-8 but not tumor necrosis factor-alpha in human adipocytes. Cytokine. 2008;41(1):29–37.

    Article  CAS  PubMed  Google Scholar 

  11. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.

    CAS  PubMed  Google Scholar 

  12. Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine. 2012;57(1):136–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res. 2009;58(11):727–36.

    Article  CAS  PubMed  Google Scholar 

  14. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88(7):3005–10.

    Article  PubMed  Google Scholar 

  15. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet. 2005;366(9501):1954–9.

    Article  CAS  PubMed  Google Scholar 

  16. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis. 2008;197(1):392–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab. 2012;38:183–91.

    Article  CAS  PubMed  Google Scholar 

  18. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and anti-inflammatory cytokines, and autoimmunity. Ann N Y Acad Sci. 2002;966:290–303.

    Article  CAS  PubMed  Google Scholar 

  19. Straznicky NE, Lambert GW, Lambert EA. Neuroadrenergic dysfunction in obesity: an overview of the effects of weight loss. Curr Opin Lipidol. 2010;21(1):21–30.

    Article  CAS  PubMed  Google Scholar 

  20. Martín-Cordero L, García JJ, Ortega E. Noradrenaline-mediated inhibition of inflammatory cytokines is altered in macrophages from obese Zucker rats: effect of habitual exercise. Endocr Metab Immune Disord Drug Targets. 2013;13(3):234–9.

    Article  PubMed  Google Scholar 

  21. Ortega E, Giraldo E, Hinchado MD, Martín L, García JJ, De la Fuente M. Neuroimmunomodulation during exercise: role of catecholamines as “stress mediator” and/or danger signal for the innate immune response. Neuroimmunomodulation. 2007;14(3–4):206–12.

    Article  CAS  PubMed  Google Scholar 

  22. Matzinger P. An innate sense of danger. Semin Immunol. 1998;10(5):399–415.

    Article  CAS  PubMed  Google Scholar 

  23. Giraldo E, Multhoff G, Ortega E. Noradrenaline increases the expression and release of Hsp72 by human neutrophils. Brain Behav Immun. 2010;24(4):672–7.

    Article  CAS  PubMed  Google Scholar 

  24. Garcia JJ, Martin-Cordero L, Hinchado MD, Bote ME, Ortega E. Effects of habitual exercise on the eHsp72-induced release of inflammatory cytokines by macrophages from obese Zucker rats. Int J Sports Med. 2013;34(6):559–64.

    CAS  PubMed  Google Scholar 

  25. Ohashi K, Shibata R, Murohara T, Ouchi N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab. 2014;25(7):348–55.

    Article  CAS  PubMed  Google Scholar 

  26. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–801.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11(11):738–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–84.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes. 2009;58(11):2574–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, et al. Pro-inflammatory CD11c + CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes. 2010;59(7):1648–56.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011;11(9):607–15.

    Article  CAS  PubMed  Google Scholar 

  33. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Martin-Cordero L, Garcia JJ, Giraldo E, De la Fuente M, Manso R, Ortega E. Influence of exercise on the circulating levels and macrophage production of IL-1beta and IFNgamma affected by metabolic syndrome: an obese Zucker rat experimental animal model. Eur J Appl Physiol. 2009;107(5):535–43.

    Article  CAS  PubMed  Google Scholar 

  35. Plotkin BJ, Paulson D, Chelich A, Jurak D, Cole J, Kasimos J, et al. Immune responsiveness in a rat model for type II diabetes (Zucker rat, fa/fa): susceptibility to Candida albicans infection and leucocyte function. J Med Microbiol. 1996;44(4):277–83.

    Article  CAS  PubMed  Google Scholar 

  36. Martin-Cordero L, Reis F, Garcia JJ, Teixeira F, Ortega E. Effect of exercise without diet on functional capacity of peritoneal macrophages and TNF-α levels in blood and in adipose tissue in the obese Zucker rat model of the metabolic syndrome. Proc Nutr Soc. 2013;72(OCE1):E76.

    Article  Google Scholar 

  37. Teixeira de Lemos E, Reis F, Baptista S, Pinto R, Sepodes B, Vala H, et al. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition. 2009;25(3):330–9.

    Article  CAS  PubMed  Google Scholar 

  38. Kawanishi N, Yano H, Yokogawa Y, Suzuki K. Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. Exerc Immunol Rev. 2010;16:105–18.

    PubMed  Google Scholar 

  39. Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med. 2003;115(Suppl 8A):6S–11.

    Article  CAS  PubMed  Google Scholar 

  40. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–7.

    Article  CAS  PubMed  Google Scholar 

  41. Funahashi T, Matsuzawa Y. Adiponectin and the cardiometabolic syndrome: an epidemiological perspective. Best Pract Res Clin Endocrinol Metab. 2014;28(1):93–106.

    Article  CAS  PubMed  Google Scholar 

  42. Wang H, Luo W, Eitzman DT. Leptin in thrombosis and atherosclerosis. Curr Pharm Des. 2014;20(4):641–5.

    Article  CAS  PubMed  Google Scholar 

  43. Herder C, Peltonen M, Svensson PA, Carstensen M, Jacobson P, Roden M, et al. Adiponectin and bariatric surgery: associations with diabetes and cardiovascular disease in the Swedish Obese Subjects Study. Diabetes Care. 2014;37(5):1401–9.

    Article  CAS  PubMed  Google Scholar 

  44. Abate N, Sallam HS, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. 2014;20(31):4961–9.

    Article  CAS  PubMed  Google Scholar 

  45. Greulich S, Chen WJ, Maxhera B, Rijzewijk LJ, van der Meer RW, Jonker JT, et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One. 2013;8(3):e59697.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Weiss IA, Valiquette G, Schwarcz MD. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes. Cardiol Rev. 2009;17(4):165–75.

    Article  PubMed  Google Scholar 

  47. Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J. 2005;150(5):859–70.

    Article  CAS  PubMed  Google Scholar 

  48. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 2011;46(4):217–24.

    Article  CAS  PubMed  Google Scholar 

  49. Rojas A, Morales MA. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci. 2004;76(7):715–30.

    Article  CAS  PubMed  Google Scholar 

  50. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302(2):179–88.

    Article  CAS  PubMed  Google Scholar 

  51. Kishida K, Funahashi T, Shimomura I. Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocr Metab Immune Disord Drug Targets. 2012;12(2):118–31.

    Article  CAS  PubMed  Google Scholar 

  52. Syvanne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 1997;350 Suppl 1:SI20–3.

    Article  PubMed  Google Scholar 

  53. Tan KC, Ai VH, Chow WS, Chau MT, Leong L, Lam KS. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab. 1999;84(9):3212–6.

    CAS  PubMed  Google Scholar 

  54. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(7):1225–36.

    Article  CAS  PubMed  Google Scholar 

  55. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  56. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117(1):43–51.

    Article  PubMed  Google Scholar 

  57. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879–84.

    Article  PubMed  Google Scholar 

  58. Varga ZV, Giricz Z, Liaudet L, Hasko G, Ferdinandy P, Pacher P. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta. 2015;1852(2):232–42.

    Article  CAS  PubMed  Google Scholar 

  59. Kobayashi S, Liang Q. Autophagy and mitophagy in diabetic cardiomyopathy. Biochim Biophys Acta. 2015;1852(2):252–61.

    Article  CAS  PubMed  Google Scholar 

  60. Duncan JG. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta. 2011;1813(7):1351–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Kok BP, Brindley DN. Myocardial fatty acid metabolism and lipotoxicity in the setting of insulin resistance. Heart Fail Clin. 2012;8(4):643–61.

    Article  PubMed  Google Scholar 

  62. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol. 1995;27(1):169–79.

    Article  CAS  PubMed  Google Scholar 

  63. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207–58.

    Article  CAS  PubMed  Google Scholar 

  64. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res. 2011;92(1):10–8.

    Article  PubMed  Google Scholar 

  65. Boudina S, Abel ED. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda). 2006;21:250–8.

    Article  CAS  Google Scholar 

  66. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes. 2007;56(10):2457–66.

    Article  CAS  PubMed  Google Scholar 

  67. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107(24):3040–6.

    Article  CAS  PubMed  Google Scholar 

  68. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) – Potsdam Study. Diabetes. 2003;52(3):812–7.

    Article  CAS  PubMed  Google Scholar 

  69. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–34.

    Article  CAS  PubMed  Google Scholar 

  70. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41(10):1241–8.

    Article  CAS  PubMed  Google Scholar 

  71. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286–92.

    Article  CAS  PubMed  Google Scholar 

  72. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.

    Article  CAS  PubMed  Google Scholar 

  73. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110(6):851–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Madhumitha H, Mohan V, Deepa M, Babu S, Aravindhan V. Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease. Cardiovasc Diabetol. 2014;13:1.

    Article  PubMed Central  PubMed  Google Scholar 

  75. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433–42.

    Article  PubMed  Google Scholar 

  76. Lo J, Bernstein LE, Canavan B, Torriani M, Jackson MB, Ahima RS, et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2007;293(1):E102–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Rosevinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol. 2007;36(2):91–6.

    Article  Google Scholar 

  78. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006;166(8):902–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005;42(6):517–25.

    Article  CAS  PubMed  Google Scholar 

  80. Paquot N, Castillo MJ, Lefèbvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab. 2000;85(3):1316–9.

    CAS  PubMed  Google Scholar 

  81. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 1996;45(7):881–5.

    Article  PubMed  Google Scholar 

  82. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011;96(1):E146–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  83. Yazdani-Biuki B, Mueller T, Brezinscheck HP, Hermann J, Graninger W, Wascher TC. Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation. Diabetes Care. 2006;29(7):1712–3.

    Article  PubMed  Google Scholar 

  84. Kiortsis D, Mavridis A, Vasakos S, Nikas S, Drosos A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005;64(5):765–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  85. Yazdani-Biuki B, Stelzl H, Brezinscheck HP, Hermann J, Mueller T, Krippl P, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest. 2004;34(9):641–2.

    Article  CAS  PubMed  Google Scholar 

  86. Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care. 2013;36(8):2239–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  87. Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35(8):1654–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  88. Rissanen A, Howard CP, Botha J, Thuren T. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab. 2012;14(12):1088–96.

    CAS  PubMed  Google Scholar 

  89. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1β inhibition with canakinumab on haemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739–48.

    Article  CAS  PubMed  Google Scholar 

  90. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2011;96(7):2119–26.

    Article  PubMed  Google Scholar 

  91. Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013;56(4):714–23.

    Article  CAS  PubMed  Google Scholar 

  92. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152(6):346–57.

    Article  PubMed Central  PubMed  Google Scholar 

  93. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008;1(1):36–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  94. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  95. Ota K, Wildmann J, Ota T, Besedovsky HO, Del Rey A. Interleukin-1beta and insulin elicit different neuroendocrine responses to hypoglycemia. Ann N Y Acad Sci. 2009;1153:82–8.

    Article  CAS  PubMed  Google Scholar 

  96. Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang NH, Morimoto C. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun. 2010;401(1):7–12.

    Article  CAS  PubMed  Google Scholar 

  97. Donath MY. Targeting inflammation in the treatment of type 2 diabetes. Diabetes Obes Metab. 2013;15 Suppl 3:193–6.

    Article  CAS  PubMed  Google Scholar 

  98. Das A, Stroud S, Mehta A, Rangasamy S. New treatments for diabetic retinopathy. Diabetes Obes Metab. 2015;17(3):219–30.

    Google Scholar 

  99. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22.

    Article  PubMed  Google Scholar 

  100. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–77.

    Article  Google Scholar 

  101. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–86.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physiology (Immunophysiology Research Group), Faculty of Sciences, University of Extremadura, Avda Elvas, s/n, 06071, Badajoz, Spain

    Eduardo Ortega Ph.D.

  2. Department of Nursing (Immunophysiology Research Group), University of Extremadura, Badajoz, Spain

    Leticia Martín-Cordero Ph.D.

  3. Department of Physiological Sciences II, Faculty of Medicine, University of Barcelona, L’Hospitalet Llobregat, Spain

    Pablo M. Garcia-Roves Ph.D.

  4. Department of Health and Exercise and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA

    Adam J. Chicco Ph.D.

  5. Diabetes and Obesity Laboratory, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain

    Alba Gonzalez-Franquesa M.Sc., Ph.D.

  6. Department of Internal Medicine – B, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

    Daniela Marado M.D.

Authors
  1. Eduardo Ortega Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leticia Martín-Cordero Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pablo M. Garcia-Roves Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adam J. Chicco Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alba Gonzalez-Franquesa M.Sc., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniela Marado M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo Ortega Ph.D. .

Editor information

Editors and Affiliations

  1. Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra University, Coimbra, Portugal

    Filipe Palavra

  2. Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra University, Coimbra, Portugal

    Flávio Reis

  3. Department of Internal Medicine – B, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

    Daniela Marado

  4. Interdisciplinary Centre of Research Egas Moniz, CiiEM, Caparica, Portugal

    Armando Sena

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ortega, E., Martín-Cordero, L., Garcia-Roves, P.M., Chicco, A.J., Gonzalez-Franquesa, A., Marado, D. (2015). Diabetes Mellitus and Metabolic Syndrome. In: Palavra, F., Reis, F., Marado, D., Sena, A. (eds) Biomarkers of Cardiometabolic Risk, Inflammation and Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-16018-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16018-4_3

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16017-7

  • Online ISBN: 978-3-319-16018-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation